Cabozantinib in Progressive Medullary Thyroid Cancer

PURPOSE: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I. PATIENTS AND METHOD...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Elisei, Rossella, Schlumberger, Martin J., Müller, Stefan P., Schöffski, Patrick, Brose, Marcia S., Shah, Manisha H., Licitra, Lisa, Jarzab, Barbara, Medvedev, Viktor, Kreissl, Michael C., Niederle, Bruno, Cohen, Ezra E.W., Wirth, Lori J., Ali, Haythem, Hessel, Colin, Yaron, Yifah, Ball, Douglas, Nelkin, Barry, Sherman, Steven I.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4164813/
https://ncbi.nlm.nih.gov/pubmed/24002501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.48.4659
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados